FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
	3235-0287
Estimated average burd	den
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)																
1. Name and Address of Reporting Person* Woo Andrew H.				2. Issuer Name and Ticker or Trading Symbol Alzamend Neuro, Inc. [ALZN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
3500 LEN	OX RD NI	E, SUITE 1500		3. Date of Earliest Transaction (Month/Day/Year) 03/15/2022						-	Officer (give	e title below)	Other	(specify below)			
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							ear)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
ATLANTA	A, GA 303	26											_ Form fried by f	wore man one i	reporting reison		
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
(Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, any (Month/Day/Yea		Date, it	(Instr.		(A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D) Ov	Owned Following Reported Transaction(s)		d C	Ownership of Form:	eneficial	
					/Year	Cod	le	V A	mount	(A) or (D)	(Ir	(Instr. 3 and 4)		0	r Indirect (I	wnership nstr. 4)	
Common S	Stock		03/15/2022				M	1)	50	0.000	A	\$ 0 10	00.000		I)	
			Table II -	Derivati				iired,	Dispos	ed of, o	or Benef						
1. Title of	2.	3. Transaction	3A. Deemed	(e.g., put	s, ca	T -	arrants, umber	-				- 	nd Amount	8 Price of	9. Number of	10.	11. Natur
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security 2. Tansaction Date (Month/Day/Year)		Execution Date, if	f Transaction Code r) (Instr. 8)				(Month/Day/Y		Oate of U /Year) Sec		of Under Securitie (Instr. 3	lying s		Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exer	cisable	Expira Date	ation	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Restricted Stock Grant	<u>(2)</u>	03/15/2022		M			50,000		(3)	03/1:	5/2022	Commo	150 000	\$ 0	0	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Woo Andrew H. 3500 LENOX RD NE, SUITE 1500 ATLANTA, GA 30326	X						

Signatures

/s/ Andrew H. Woo	03/16/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the vesting of restricted stock.
- (2) Each restricted stock unit is the economic equivalent of one share of Common Stock, par value \$0.0001, of Alzamend Neuro, Inc.

(3) 2,778 and 47,222 restricted shares previously vested on September 13, 2021 and October 13, 2021, respectively, with the final 50,000 shares of restricted stock vesting on March 15, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.